Company intelligence / Profile preview

Farsight Medical Technology (Shanghai) Co., Ltd.

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

The lead program CC‑4066 targets prevention of delayed graft function post-kidney transplant and other acute organ injuries. Human trials were scheduled to begin in China in early 2021. No published late-stage results found.[1]

Therapeutic areas: OtherGastroenterologyNephrology
Modalities: Small molecules, specifically cyclophilin inhibitors and cyclosporin analogs[7][1]
Industry: Biotech

Drug pipeline

1 asset

CC-4066

IND

Indications: Delayed Graft Function, Organ Preservation, Acute Kidney Injury, Acute Pancreatitis

Partnerships

Cypralis Ltd. — strategic partnership for access to compound library and joint development of cyclophilin inhibitors.[4][1]

Beyond the preview

Go deeper on Farsight Medical Technology (Shanghai) Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Farsight Medical Technology (Shanghai) Co., Ltd..

Explore the full profile